{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:35:08Z","timestamp":1775032508852,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.08.014","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T18:00:58Z","timestamp":1473703258000},"page":"e275-e280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Moshe C.","family":"Ornstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Elson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Allman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.08.014_bib1","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.08.014_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.08.014_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.08.014_bib5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","article-title":"Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","article-title":"Moving towards dose individualization of tyrosine kinase inhibitors","volume":"37","author":"Klumpen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.08.014_bib8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdv030","article-title":"Alternate sunitinib schedules in patients with metastatic renal cell carcinoma","volume":"26","author":"Kalra","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.08.014_bib10","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib12","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2013.53.0204","article-title":"Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients","volume":"32","author":"Prasad","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib13","unstructured":"ClinicalTrials.gov. NCT01499121\u2014Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01499121. Accessed: July 29,\u00a02016."},{"key":"10.1016\/j.clgc.2016.08.014_bib14","unstructured":"ClinicalTrials.gov. NCT02579811\u2014Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02579811?term=axitinib&recr=Open&rank=9. Accessed July 29,\u00a02016."},{"key":"10.1016\/j.clgc.2016.08.014_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.08.014_bib16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib17","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S1470-2045(15)00543-4","article-title":"Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma","volume":"17","author":"Motzer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.08.014_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.breast.2014.06.003","article-title":"Impact of trastuzumab treatment beyond disease progression for advanced\/metastatic breast cancer on survival\u2014results from a prospective, observational study in Germany","volume":"23","author":"Jackisch","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.clgc.2016.08.014_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1634\/theoncologist.2009-0029","article-title":"Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study","volume":"15","author":"Extra","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2016.08.014_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdt572","article-title":"Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC","volume":"25","author":"Ou","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3748\/wjg.v18.i7.698","article-title":"Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients","volume":"18","author":"Li","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clgc.2016.08.014_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jjco\/hyn134","article-title":"Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor","volume":"39","author":"Park","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.08.014_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1535-7163.MCT-14-0208","article-title":"Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is\u00a0associated with epigenetic modifications","volume":"14","author":"Adelaiye","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2016.08.014_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clgc.2016.08.014_bib26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.08.014_bib27","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","article-title":"A\u00a0long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients","volume":"18","author":"Eechoute","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.08.014_bib28","unstructured":"Yu H, van Erp NP, Bins S, et\u00a0al. Development of a pharmacokinetic model for pazopanib\u2014a tyrosine kinase inhibitor used for the treatment of solid tumours. Population Approach Group in Europe 2016 Annual Meeting. 2016; abstract\u00a05926."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:46Z","timestamp":1761564466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316302488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316302488"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.014","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}